Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

fostamatinib

- PMLiVE

EMA grants AZ’s Vaxzevria COVID-19 vaccine full marketing authorisation

Vaxzevria has been shown to be effective against all forms of COVID-19

Expanding Opportunities for Healthcare with “Digital Twins”

Brad Womble, Senior Director of Strategy, Marketing and Mergers & Acquisitions, at Jabil Healthcare dives into several thought-provoking topics, including how insights from “digital twins” can be used to improve...

Impetus Digital

- PMLiVE

Innovative Trials on the latest ABPI report

Kate Shaw, Innovative Trials Founder & CEO, commented on the latest ABPI report

Innovative Trials

- PMLiVE

Alexion’s Ultomiris shows promise in neuromyelitis optica spectrum disorder phase 3 trial

Ultomiris-treated patients showed zero relapses with a median treatment duration of 73 weeks

- PMLiVE

AstraZeneca’s two advanced breast cancer trials meet primary endpoints

Both trials showed significant improvement in progression-free survival

- PMLiVE

New study links genetic traits of Black Death survivors and autoimmune diseases today

The study involved the extraction and screening of more than 500 ancient DNA samples

- PMLiVE

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer

Phase 3 trial results demonstrated a 22% reduction in risk of death versus sorafenib

- PMLiVE

Innovative Trials featuring in a Clinical Trials Arena article

Leanne Keem, Head of Operations and Client Relationship at Innovative Trials, featured in a recent article.

Innovative Trials

- PMLiVE

Amgen completes acquisition of ChemoCentryx in deal worth $3.7bn

Amgen gains access to the biopharma’s autoimmune disease treatment Tavneos

- PMLiVE

Incyte to acquire Villaris Therapeutics to expand inflammation and autoimmunity portfolio

Auremolimab, which has proven efficacy for vitiligo, is included in the deal

Overcoming Patient Recruitment Challenges in Rare Disease Trials

Rare diseases are thought to affect up to 446 million people worldwide. With more than 7,000 rare diseases, most of which are genetic, it’s vital all patients can access new...

Innovative Trials

- PMLiVE

AstraZeneca’s Tezspire receives MHRA approval as add-on treatment for severe asthma

Tezspire demonstrated reduced annualised rate of asthma exacerbations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links